The Prevalence of Hepatitis B and C Among Prisoners in Kahramanmaras, Turkey

Keten, Derya; Ova, Mehmet Emin; Keten, Hamit Sırrı; Keten, Alper; Gulderen, Evrim; Tümer, Seray; Çalışkan, Ahmet; Kulotu, Suleyman

doi:10.5812/jjm.31598

Cited by 21 publications

(18 citation statements)

References 28 publications

(26 reference statements)

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Similar results were reported among the prisoners in Turkey by Keten et al, 2016 (14) who found that Anti-HCV was positive in 17.7% but it was higher regarding our HBc antigen seroprevalence as it showed 2.6% HBsAg positivity. Adjei et al, 2006 (15) revealed similar seroprevalence of HCV (19.0%) while the HBsAg recorded 17.4% in prisons in Ghana, the difference in the prevalence of HBV may be attributed to the difference in the marker used for diagnosis.…”

Section: Discussionsupporting

confidence: 90%

Hepatitis B and C Viral Infections among prisoners: Prevalence and Associated Risk Factors

Ibraheem

2018

The Egyptian Family Medicine Journal

View full text Add to dashboard Cite

Back ground: Blood borne diseases are generally higher in prisons than in the community as prisoners in jails usually come from low social class. Understanding the risk factors of hepatitis B viral (HBV) and hepatitis C viral (HCV) infections among prisoners could help improve their interventions. Objectives: This study aimed to estimate the prevalence of HBV and HCV infections among prisoners and to determine associated risk factors in the prison environment. Methods: A total number of 324 prisoners, who were incarcerated in Shebin Elkom general prison, were included in this study. Questions about personal data and risk factors for blood born infections were asked and all subjects were investigated for hepatitis B core antigen and hepatitis C antibody. Results: Among prisoners, the prevalence of HBV, HCV infections, and HBV/ HCV co-infections were 8.02%, 16.4% and 1.9% respectively. The HBV and HCV infections were significantly associated with history of tattooing, dental procedures and surgery. Using binary logistic regression model, it was shown that imprisonment duration and tattooing were independent risk factors for both HCV and HBV infections. Conclusion: Tattoos, use of shared personal tools and other circumstances that facilitate blood contact, which is especially present in prisons, increase HBV and HCV infection risk among prisoners. These results should promote consideration of routine HBV and HCV screening and behavioral interventions among the incarcerated.

show abstract

Section: Discussionsupporting

confidence: 90%

Hepatitis B and C Viral Infections among prisoners: Prevalence and Associated Risk Factors

Ibraheem

2018

The Egyptian Family Medicine Journal

View full text Add to dashboard Cite

show abstract

“…Prisoners Prisoners are a vulnerable population and are among the potential priority at-risk populations for micro-elimination [35]. The continued use of drugs and shared syringes, getting new tattoos, and other incidents that cause contact with blood increase the risk of bloodborne infections among prisoners [27]. A national plan formulated jointly by both the Ministry of Health and Ministry of Justice should include training of health-care providers in prisons, screening of prisoners and defining the methodology to access treatment.…”

Section: People With High-risk Behavioursmentioning

confidence: 99%

A micro-elimination approach to addressing hepatitis C in Turkey

İdilman

Razavi

Robbins-Scott

et al. 2020

BMC Health Serv Res

View full text Add to dashboard Cite

Background: In 2016, WHO passed the Global Health Sector Strategy on Viral Hepatitis (GHSS), calling for its elimination by 2030. Two years later, Turkey approved a strategy to reach the WHO targets. This study reports new national prevalence data, breaks it down by subpopulation, and models scenarios to reach HCV elimination. Methods: Literature was reviewed for estimates of HCV disease burden in Turkey. They were discussed with stakeholders and used as inputs to develop a disease burden model. The infected population was estimated by sequelae for the years 2015-2030. Three scenarios were developed to evaluate the disease burden in Turkey: a Base 2017 scenario, representing the current standard of care in Turkey; an increased treatment scenario, representing the impact of improved access to DAAs; and a WHO targets scenario, which meet the WHO GHSS viral hepatitis targets of a 65% reduction in mortality and 90% diagnosis rate of the infected population by 2030. Results: At the beginning of 2017, 271,000 viremic infections were estimated. Of these, 58,400 were diagnosed and 10,200 treated. Modelling results showed that, with the current treatment paradigm in Turkey, by 2030 the total number of viremic HCV infections would decline by 35%, while liver-related deaths, hepatocellular carcinoma (HCC), and decompensated cirrhosis would decrease by 10-25%. In the increased treatment scenario, by 2030 viremic HCV infections would decrease by 50%; liver-related deaths, HCC and decompensated cirrhosis would decrease by 45-70%. In the WHO targets scenario, HCV infections would decrease by 80%; sequelae would decrease by 80-85%. Data on disease burden in micro-elimination target subpopulations are largely unavailable. Conclusions: To meet the WHO Global Health Sector Strategy targets for the elimination of HCV, Turkey needs to increase treatment. Better data are needed as well as countrywide access to DAAs.

show abstract

“…However from the article it is unclear whether the sample was selected from all incarcerated individuals or those presumed to be at higher risk a priori based on nature of the crime leading to incarceration [12]. …”

Section: Prevalence In the Rest Of The Worldmentioning

confidence: 99%

Epidemiology and Treatment of Hepatitis B in Prisoners

Smith

Uvin

Macmadu

et al. 2017

Curr Hepatology Rep

View full text Add to dashboard Cite

Purpose of Review The review details recent literature reports regarding Hepatitis B Virus (HBV) and, in particular, Hepatitis B prevalence/incidence in incarcerated populations around the world. Furthermore, the review will summarize the national/international guidelines regarding HBV and look at diagnosis, vaccination, treatment, and linkage to care after release. Recent Findings HBV affects prisoners at a much higher rate than the general populations. Many who are at increased risk for HBV infection are also at increased risk for incarceration. Incarcerated settings also have higher rates of HBV transmission. Summary Incarcerated individuals should be immunized if they are not already immune to HBV. Increased access to safe injecting and tattoo paraphernalia, condoms, and personal hygiene equipment could reduce the spread of HBV and other blood-borne and sexually transmitted infections. Future research should focus on ways to prevent the spread of HBV and similar viruses in incarcerated settings in order to protect incarcerated individuals and the general public. Research on effective linkage to community HBV care following release is needed.

show abstract

The Prevalence of Hepatitis B and C Among Prisoners in Kahramanmaras, Turkey

Cited by 21 publications

References 28 publications

Hepatitis B and C Viral Infections among prisoners: Prevalence and Associated Risk Factors

Hepatitis B and C Viral Infections among prisoners: Prevalence and Associated Risk Factors

A micro-elimination approach to addressing hepatitis C in Turkey

Epidemiology and Treatment of Hepatitis B in Prisoners

Contact Info

Product

Resources

About